Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 Inhibitors in Malignant Cancer Patients: Does PD-L1 Matter?

Background: Combination therapy with immune checkpoint inhibitors (ICIs) has been widely used for clinical treatment in recent years, which has a better survival benefit. However, not all patients can derive clinical benefit from combination immunotherapy. Therefore, it is necessary to explore the b...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Front Pharmacol
Главные авторы: Feng, Yuqian, Jin, Huimin, Guo, Kaibo, Xiang, Yuying, Zhang, Yiting, Du, Wurong, Shen, Minhe, Ruan, Shanming
Формат: Artigo
Язык:Inglês
Опубликовано: Frontiers Media S.A. 2021
Предметы:
Pharmacology
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7949479/
https://ncbi.nlm.nih.gov/pubmed/33716732
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2021.572845
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы